Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Balloon pulmonary angioplasty beats riociguat in randomized CTEPH trial

Key clinical point: Balloon pulmonary angioplasty (BPA) was found more effective than riociguat for nonoperable chronic thromboembolic pulmonary hypertension.

Major finding: Relative to riociguat, BPA reduced pulmonary vascular resistance by 40% (P less than .0001) at the end of a 26-week trial.

Data Source: Multicenter, randomized, open-label trial.

Disclosures: Dr. Jaïs reported no potential conflicts of interest.

Citation:

Jaïs X. ERS 2019.